AIM ImmunoTech Inc

ASE:AIM   3:59:50 PM EDT
1.89
-0.04 (-2.07%)
Products, Regulatory

AIM Immunotech Provides Clinical Updates On Planned Phase 2 Study Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer

Published: 10/04/2021 13:55 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients With Locally Advanced Or Metastatic Late-stage Pancreatic Cancer.
Aim Immunotech Inc - Finalizes and Reports Phase 2 Study Protocol.
Aim Immunotech Inc - Expects to Submit Ind and Apply for Fast Track Status With FDA by October 18, 2021.